Achieve Life Sciences, Inc. operates as a pharmaceutical company. The Company develops and commercializes cytisine treatment to help people battling nicotine addiction. Achieve Life Sciences serves customers in North America.

S-3 | Registration statement for specified transactions by certain issuers

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Achieve Life Sciences (ACHV US)

S-3 | Registration statement for specified transactions by certain issuers

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-07)

Current Report (Form 8-K | Period ending 2024-09-27)

424B5 | Prospectus

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)